Levodopa is the most effective medication for the treatment of the motor symptoms of Parkinson’s disease. However, over time, the clinical response to levodopa becomes complicated by a reduction in the duration and reliability of motor improvement (motor fluctuations) and the emergence of involuntary movements (levodopa-induced dyskinesia). Strategies that have been attempted in an effort to delay the development of these motor complications include levodopa sparing and continuous dopaminergic therapy. Once motor complications occur, a wide array of medical treatments is available to maximize motor function through the day while limiting dyskinesia. Here, we review the clinical features, epidemiology, and risk factors for the development of motor complications, as well as strategies for their prevention and medical management.

左旋多巴是治疗帕金森病运动症状最有效的药物。然而，随着时间的推移，左旋多巴的临床反应因运动改善（运动波动）的持续时间和可靠性的减少以及不自主运动（左旋多巴引起的运动障碍）的出现而变得复杂。已尝试延迟这些运动并发症发展的策略包括保留左旋多巴和持续多巴胺能治疗。一旦出现运动并发症，就可以使用多种药物治疗来最大限度地提高一天中的运动功能，同时限制运动障碍。在这里，我们回顾了运动并发症的临床特征、流行病学和危险因素，以及预防和医疗管理的策略。